iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3
Yahoo Finance · Mar 20, 2026 · iBio, Inc. Common Stock (IBIO)
Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy for heart failure, with an initial focus on pulmonary hypertension associated with heart failure wit
Not investment advice. Cached headline, not a full reprint.